Navigation Links
Thomas, McNerney & Partners Promotes Three Members of Its Investment Team
Date:1/8/2009

Kathy Tune Promoted to Principal. Christine Siu and Jason Brown, Ph.D. Promoted to Vice President

MINNEAPOLIS, SAN FRANCISCO and STAMFORD, Conn., Jan. 8 /PRNewswire/ -- Thomas, McNerney & Partners, a health care venture capital firm that invests in life science and medical technology companies, today announced the promotion of three members of its investment team. Kathy Tune has been promoted to Principal. Christine Siu and Jason Brown have been promoted to Vice President.

"We are pleased to announce the promotion of these three valuable members of our investment staff," said James Thomas, Partner. "Each of these individuals has made important contributions to the firm and these promotions recognize both their development as professionals and the growth and maturity of the firm and its investment team."

Kathy Tune joined the firm's Minneapolis office in 2003 and focuses her investment practice on the medical device sector. Kathy was previously with Piper Jaffray and Solvay. Kathy is a board member of Softscope Medical Technologies, Inc. Her educational background includes an M.S. degree in Microbiology from the University of Minnesota and an M.B.A. from the University of Minnesota's Carlson School of Management, where she was a Robert and Gail Buuck Scholar.

Christine Siu joined the firm's Connecticut office in 2005 and focuses her investment activities on venture opportunities in the public and late-stage private markets. Prior to Thomas, McNerney, Christine was at Warburg Pincus and Bear Stearns. Christine is a graduate of the University of Michigan with a B.S. with distinction in Cellular Molecular Biology and Economics and holds an M.B.A. from Harvard Business School.

Jason Brown joined Thomas, McNerney's San Francisco office in 2007 and focuses his investment practice in the biopharmaceutical sector. Jason previously spent four years at Forward Ventures and conducted research in antimicrobial drug discovery and bacterial genomics as a postdoctoral fellow in Infectious Diseases at Johnson & Johnson Pharmaceutical Research and Development. He is currently a board member of Altair Therapeutics, Inc. Jason earned a Ph.D. in Biology at the University of California, San Diego, where he was a National Science Foundation Fellow, and a B.S. in Molecular Biology and Biochemistry from Purdue University.

About Thomas, McNerney & Partners

Thomas, McNerney & Partners is a health care venture capital firm with approximately $600 million under management, focused on investing in life science and medical technology companies at all stages of development. In addition to helping entrepreneurs launch companies with seed and early-stage funding, the firm provides growth capital to emerging companies to advance clinical development or for product commercialization. Thomas, McNerney & Partners also is involved in spinning out products and divisions from major medical device and pharmaceutical companies, consolidating companies through roll-up strategies and participating in structured financings for public companies, as well as recapitalizations. The firm is targeting investments in the pharmaceutical, medical device, biotechnology and diagnostic sectors and in other areas utilizing medical technology innovation. The firm has offices in Stamford, Minneapolis and San Francisco.

For further information, please visit www.tm-partners.com.


'/>"/>
SOURCE Thomas, McNerney & Partners
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
3. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
4. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
5. AtriCure to Present at Roth Capital Partners 2007 New York Conference
6. MDS to Present at Thomas Weisel Partners Healthcare Conference
7. Lutheran Senior Services Partners with Silverchair Learning Systems to Enhance Employee Training and Education
8. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. National Patient Safety Foundation Partners with Vocera Communications
11. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology: